Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Debiopharm Group

Evaluate

Thumbnail
July 29, 2022

No place for Wee1 in Astra’s synthetic lethality work

Wee1 competitors including Zentalis might look with trepidation on Astra and Roche’s recent moves into ATR inhibition.

Thumbnail
February 02, 2022

Up-front licensing costs hit a five-year high

But the pace of biopharma asset deals dips. Are the two trends related?

Article image
Vantage logo
September 16, 2021

Esmo 2021 – Astra finally sees a Wee1 signal

It might be too late for adavosertib, but others could benefit if a niche has finally been found for Wee1 inhibitors.

Article image
Vantage logo
November 11, 2020

Five Prime looks to turn a corner

Survival data with bemarituzumab see the company erase half of the past three years’ losses.

Article image
Vantage logo
June 11, 2020

New Genmab/Abbvie tie-up rings old bells

Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.

Article image
Vantage logo
September 05, 2019

Esmo 2019 preview – Parps on parade

Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.

Vantage logo
March 16, 2017

Corporate venture capital – saviour of medtech?

Vantage logo
April 15, 2015

Biocartis flies the flag with unusual Brussels medtech listing

Vantage logo
January 29, 2014

Innovation threatened as medtech sees no improvement in venture funding

Vantage logo
November 07, 2013

Curis hit badly by cancer drug clinical hold

Vantage logo
September 26, 2013

With Infinity’s failure, spotlight falls on Synta

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up